Results 11 to 20 of about 21,140 (245)
Health disparities in chronic liver disease
Hepatology, EarlyView., 2022 Abstract The syndemic of hazardous alcohol consumption, opioid use, and obesity has led to important changes in liver disease epidemiology that have exacerbated health disparities. Health disparities occur when plausibly avoidable health differences are experienced by socially disadvantaged populations.
Ani Kardashian +3 more
wiley +1 more source
Emergency department-initiated oral naltrexone for patients with moderate to severe alcohol use disorder: A pilot feasibility study. [PDF]
Acad Emerg MedAbstract Objectives Alcohol use disorder (AUD) is the most common substance use disorder in the United States. Despite availability of four FDA‐approved medications, fewer than 10% of patients are prescribed medication. This study aimed to evaluate the impact and feasibility of emergency department (ED)‐initiated oral naltrexone in patients with ...
Cowan E +6 more
europepmc +2 more sources
Naltrexone Implant for Opioid Use Disorder
Neurology International, 2021 The continued rise in the availability of illicit opioids and opioid-related deaths in the United States has left physicians, researchers, and lawmakers desperate for solutions to this ongoing epidemic.
Amber N. Edinoff +10 more
doaj +1 more source
Low-dose and high-dose naltrexone in opioid dependence syndrome: a three months outcome study
Open Journal of Psychiatry and Allied Sciences, 2019 Background: Naltrexone is effective in the treatment of opioid dependence syndrome (ODS) as it prevents relapse. To effectively design a cost-effective treatment modality for ODS using naltrexone as low as 25 mg is something which is worth exploring. Aim:
Ajeet Sidana +2 more
doaj +1 more source
Opioid-positive urine drug screen during treatment with oral naltrexone and the clinical implications [PDF]
Mental Health ClinicianIntroduction Naltrexone is an opioid antagonist that is FDA approved to treat alcohol dependence and opioid dependence. It is available as an oral tablet and an extended-release injectable suspension.
Elena R. Beauregard, PharmD, BCPS +1 more
doaj +1 more source
Diabetes, Metabolic Syndrome and Obesity, 2022 Sarah Dahlberg,1 Ellen T Chang,1 Sheila R Weiss,1 Pamela Dopart,1 Errol Gould,2 Mary E Ritchey3 1Exponent, Inc, Menlo Park, CA, 94025, USA; 2Currax Pharmaceuticals LLC., Brentwood, TN, 37027, USA; 3Med Tech Epi, LLC., Philadelphia, PA, 19147 ...
Dahlberg S +5 more
doaj
Hidden Markov models for alcoholism treatment trial data [PDF]
Annals of Applied Statistics 2010, Vol. 4, No. 1, 366-395, 2010 In a clinical trial of a treatment for alcoholism, a common response variable of interest is the number of alcoholic drinks consumed by each subject each day, or an ordinal version of this response, with levels corresponding to abstinence, light drinking and heavy drinking.
arxiv +1 more source
Drugs in R&D, 2010 In March 2010, Orexigen(R) Therapeutics submitted a new drug application (NDA) for approval of naltrexone sustained release (SR)/bupropion SR (Contrave(R)) for the treatment of obesity in the US. The tablet contains naltrexone SR 32 mg and bupropion SR 360 mg.
openaire +2 more sources
The effects of Naltrexone among alcohol non-abstainers: results from the COMBINE Study
Frontiers in Psychiatry, 2010 These analyses of the COMBINE Study examined the effects of naltrexone among non-abstainers. Given that one of the most well-established mechanisms of action of naltrexone involves blunting of alcohol reward, it is hypothesized that naltrexone should be ...
Lara Ray +2 more
doaj +1 more source
Asymmetric synthesis of (−)-naltrexone
Chemical Science, 2019 The asymmetric synthesis of (−)-naltrexone was achieved by a Rh(i)-catalyzed C–H alkenylation and torquoselective electrocyclization cascade and late-stage C–H hydroxylation.
Sun Dongbang +2 more
openaire +3 more sources